Evidence map›Paper›PMID 30134198›Full record

ArticleImmunity2018

Tip Your Cap for Ebola Virus Neutralization.

Sonja M Best, Heinz Feldmann

Abstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Immunity, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Sonja M BestLaboratory of Virology, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 903 S. Fourth St., Hamilton, MT, USA. Electronic address: sbest@niaid.nih.gov.
Heinz FeldmannLaboratory of Virology, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 903 S. Fourth St., Hamilton, MT, USA.

Funding

Viral Hemorrhagic Fevers: Disease Modeling and TransmissionZIAAI001089 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI FELDMANN, HEINRICH · 2009 to 2025
$50.7M
Virus-Host Interactions: Induction and Evasion of Host Innate ImmunityZIAAI001125 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI BEST, SONJA · 2010 to 2025
$28.1M
CAP: Trivalent Filovirus Vaccine for Pre- and Post-Exposure VaccinationZIAAI001163 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI FELDMANN, HEINRICH · 2012 to 2019
$3.9M
Intramural NIH HHS Z99 AI999999Intramural NIH HHS ZIA AI001089
6 · The paper itself

Abstract

Outbreaks of Ebola virus disease are caused by multiple virus species although current therapeutic monoclonal antibodies (mAb) are essentially limited to treating one species, Zaire ebolavirus. In this issue of Immunity, Gilchuk et al. (2018) identify new mAbs with potent cross-neutralizing activity against three ebolavirus species pathogenic to humans.

Indexed as

Hemorrhagic Fever, EbolaAnimalsAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralEbolavirusGlycoproteinsHumansAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralGlycoproteins

Identifiers

PMID30134198
PMCPMC11078264

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.